Equities analysts expect Neuronetics Inc (NASDAQ:STIM) to post earnings of ($0.36) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Neuronetics’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.35). The firm is expected to issue its next earnings report on Tuesday, February 5th.
According to Zacks, analysts expect that Neuronetics will report full year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($2.11) to ($1.66). For the next year, analysts expect that the company will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.29) to ($1.18). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Neuronetics.
Neuronetics (NASDAQ:STIM) last released its quarterly earnings results on Tuesday, November 6th. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.11. The firm had revenue of $13.74 million for the quarter, compared to analysts’ expectations of $12.68 million.
Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Neuronetics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Saturday, November 10th. BTIG Research reaffirmed a “buy” rating and set a $33.00 price target on shares of Neuronetics in a research report on Wednesday, November 7th. JMP Securities lifted their price target on shares of Neuronetics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, August 15th. Finally, Canaccord Genuity lifted their price target on shares of Neuronetics from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, August 15th. Six research analysts have rated the stock with a buy rating, Neuronetics currently has a consensus rating of “Buy” and a consensus price target of $34.50.
Hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new position in Neuronetics in the second quarter valued at $133,000. American International Group Inc. purchased a new position in shares of Neuronetics during the 3rd quarter worth approximately $136,000. Pier Capital LLC purchased a new position in shares of Neuronetics during the 2nd quarter worth approximately $186,000. United Services Automobile Association purchased a new position in shares of Neuronetics during the 2nd quarter worth approximately $266,000. Finally, Granahan Investment Management Inc. MA purchased a new position in shares of Neuronetics during the 2nd quarter worth approximately $266,000. 69.16% of the stock is currently owned by hedge funds and other institutional investors.
Shares of STIM stock traded down $0.22 during trading on Monday, hitting $19.67. 93,254 shares of the stock traded hands, compared to its average volume of 135,110. The company has a quick ratio of 7.46, a current ratio of 7.63 and a debt-to-equity ratio of 0.33. Neuronetics has a 52-week low of $15.40 and a 52-week high of $39.39.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Read More: Day Trading – Risk Worth the Reward?
Get a free copy of the Zacks research report on Neuronetics (STIM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.